Primobolan 25 mg MultiPharm

Primobolan 25 mg MultiPharm uses Primobolan (methenolone acetate) in tablet form. It differs from other oral steroids in that it has no toxic effects on the liver. Taking the hormone in tablet form is much more convenient than taking injections. But these are not the only benefits of this steroid.

Main positive properties of Primobolan 25 mg MultiPharm

Methenolone is a derivative of dihydrotestosterone. It has a fairly high anabolic rate, while androgenic activity is reduced.

The anabolic effect (muscle mass gain) appears gradually. The drug is mildly acting. It is most often used for cutting cycles, where the anabolic properties help to maintain mass while eliminating excess fluid and fat.

A great advantage of the drug is that Primobolan does not have a regression phenomenon. Therefore, after you stop taking this drug, the results will remain.

Side effects

This steroid is one of the safest. It causes negative reactions only if high doses are used. Main side effects:

• slight decrease in endogenous testosterone production;
• slight increase in bad cholesterol level;
• mood changes: aggressiveness, irritability;
• mild manifestations of androgenic side effects.

Currently, it is one of the safest drugs athletes can choose to cut.

Grip recommendations

Primobolan 25 mg MultiPharm should be taken daily to maintain the same concentration of the active substance in the blood. The average dose is 50-100 mg per day.

The duration of the course, on average, is up to 8 weeks. Post-cycle therapy is performed a few days after taking the last pill.

Before use, be sure to consult with your doctor to rule out contraindications. Do not use more than the recommended dose as this may lead to an overdose.

List of references

1. Heinkele G, Schnabel PG, Wilffert B, Degenhardt M, Moller MR, Bogenschutz MP. Methenolone in the treatment of inoperable carcinoma of the mamma: clinical findings and endocrine investigations. Oncology. 1987;44(5):318-322.
2. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxymetholone and megesterol acetate for the treatment of acquired immunodeficiency syndrome-related wasting. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(4):414-423.
3. Yamada M, Morimoto M, Aida K, Wada M, Uchiyama H. Detectability of methyltestosterone and 1-methylandrostenedione as urinary markers of metenolone misuse by means of carbon isotope ratio mass spectrometry. J Steroid Biochem Mol Biol. 2014;143:300-308.
4. Schänzer W, Geyer H, Donike M. Metabolism of metenolone in man: identification and synthesis of conjugated excreted urinary metabolites, gas chromatographic-mass spectrometric identification of bis-hydroxylated metabolites isolated from the urine of a metenolone user, mass spectrometric characterization of bis-hydroxylated metabolites isolated from the urine of a human user, gas chromatographic-mass spectrometric identification of long-term metabolites in the urine of a metenolone user. J Steroid Biochem. 1989;32(2):257-266.
5. Kim L, Kunkel H, Jensen J, et al. The influence of the anabolic steroid, nandrolone, on delta 4-3-ketosteroid-5-alpha-oxidoreductase activity in the accessory organs of the rat. Acta Endocrinol (Copenh). 1982;101(1):108-112.